BioAgilytix officials say the company's expansion strengthens its ability to support biopharma partners at every stage of ...

Study suggests gasdermin D inhibition may protect mice by blocking release of cellular contents into the extracellular ...

Using neem tree extracts as a starting point, scientists have created several kinds of nanozymes and tested them for ...

The increased genetic complexity and similarity to adult cancers’ genetic diversity could also present new therapeutic opportunities.

Absci has entered the clinic with its AI-designed antibody, dosing first volunteers in a trial targeting TL1A for ...

Early research shows that editing expanding trinucleotide repeats halts the lengthening process that causes neurological ...

A scientist says he has shown that it’s possible to produce a large amount of virus-like particles using a fully scalable ...

T therapies is an expensive business. The fundamental problem is that CAR-T production is not a good fit for centralized manufacturing.

Single-use continuous bioprocessing can reduce mAb production costs and shorten time-to-market compared to batch processing.

Wacker and Expression Manufacturing want to offer clients with an end-to-end, optimized solution for viral vector development and production.

The first systematic genome-wide association study for pseudogout has identified two genes strongly associated with disease ...

How CD4+ T cells respond to Chikungunya virus may trigger long-lasting joint pain, mimicking autoimmune disease long after ...